Whitepapers

Chronic inflammation is a fundamental, underlying feature of many neurological, metabolic and autoimmune disorders. This whitepaper explores the therapeutic potential of Beta-Caryophyllene (BCP) in addressing chronic inflammation.

Cardiovascular diseases (CVDs) are the leading cause of death globally. 17.9 million people die from CVDs, an estimated 32% of all deaths worldwide. BCP activates the endocannabinoid type 2 receptor (CB2R) which regulates every immune cell in the body and produces a cardio-protective effect. It also activates many receptors throughout the body that regulate pain and metabolism including nuclear metabolic receptors PPAR-α & PPAR-γ, opioid receptors, TRPV1, serotonin 5-HT1a, nerve growth factor TrkA even as it inhibits inflammatory receptors TLR4 and NLRP3 inflammasome. BCP research experiments indicate potential protection against atherosclerosis and heart attacks.

Soldiers and competitive athletes must maintain extremely high levels of physical and mental fitness for best performance and survival. Physical stress needs to be managed to achieve optimum improvements while avoiding injury or significant inflammation impairment. In addition, neurologic function must be optimized for mental and visual focus, anxiety, sleep, and mood. Beta-Caryophyllene (BCP) appears to meet this broad-spectrum demand without adverse effects.

Medical research has shown that a compound called β-Caryophyllene (BCP) has been extensively studied in relation to neurodegeneration. BCP works through multiple pathways that include reducing oxidative stress (which is harmful to cells), reducing inflammation in the brain, protecting cells from damage, promoting the process of cleaning up damaged cells (autophagy), supporting the immune system, improving the function of mitochondria (the energy centers of cells), regulating metabolism, reinforcing blood brain barrier function, and preventing the misfolding of proteins (which can lead to neurodegeneration).

Mast Cell Activation Syndrome (MCAS) is characterized by overactive mast cells that release too many chemicals at inappropriate times. When mast cells are activated too easily or inappropriately, the potent compounds they secrete can create serious health disorders that range from chronic fatigue, gastrointestinal issues, immune disorders, allergic sensitivities to neurological problems. Beta-Caryophyllene suppresses the IgE-independent pathway by activating the CB2 receptor on the mast cell along with adiponectin pathways. With the IgE pathway blocked, the mast cell is then prevented from releasing mediators.11 Beta-Caryophyllene is a strong agonist for CB2 receptors. Its activation shifts the immune system from inflammatory to resolution phase. In addition, BCP turns off allergic reactions even to the point of inhibiting anaphylaxis, the most serious type of reaction that can occur.